Trials / Unknown
UnknownNCT04574817
Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)
A Single-arm, Open-lable, Multicenter, Phase II Clinical Study of HX008 in Subjects With Anaplastic Thyroid Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- Taizhou Hanzhong biomedical co. LTD · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
There are currently no target therapies approved for treatment of anaplastic thyroid cancer (ATC), leading to a clear need for improving therapy for ATC. This is a single-arm, multicenter study to evaluate the efficacy and safety of HX008 injection in patients with metastatic or locally advanced anaplastic thyroid cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HX008 | 200 mg administered as IV infusion on Day 1 of each 21-day cycle. |
Timeline
- Start date
- 2020-12-28
- Primary completion
- 2022-05-30
- Completion
- 2023-05-30
- First posted
- 2020-10-05
- Last updated
- 2020-10-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04574817. Inclusion in this directory is not an endorsement.